These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12522445)

  • 21. Viral gene therapy strategies: from basic science to clinical application.
    Young LS; Searle PF; Onion D; Mautner V
    J Pathol; 2006 Jan; 208(2):299-318. PubMed ID: 16362990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
    Thorne SH; Contag CH
    Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
    Wisher M
    Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Oncolytic viruses for genetic therapy of gastrointestinal tumors].
    Bitzer M; Lauer UM
    Z Gastroenterol; 2003 Jul; 41(7):667-74. PubMed ID: 12858239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.
    Thorne SH; Hermiston T; Kirn D
    Semin Oncol; 2005 Dec; 32(6):537-48. PubMed ID: 16338419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent progress in the battle between oncolytic viruses and tumours.
    Parato KA; Senger D; Forsyth PA; Bell JC
    Nat Rev Cancer; 2005 Dec; 5(12):965-76. PubMed ID: 16294217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapeutics: the future of brain tumor therapy?
    Cutter JL; Kurozumi K; Chiocca EA; Kaur B
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1053-64. PubMed ID: 16831077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in oncolytic viral therapy.
    Woo Y; Adusumilli PS; Fong Y
    Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential of oncolytic virus therapy for pancreatic cancer.
    Kasuya H; Takeda S; Nomoto S; Nakao A
    Cancer Gene Ther; 2005 Sep; 12(9):725-36. PubMed ID: 15818382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccinia virus and oncolytic virotherapy of cancer.
    Thorne SH; Hwang TH; Kirn DH
    Curr Opin Mol Ther; 2005 Aug; 7(4):359-65. PubMed ID: 16121702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic virotherapy for cancer treatment: challenges and solutions.
    Davis JJ; Fang B
    J Gene Med; 2005 Nov; 7(11):1380-9. PubMed ID: 16025557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
    Wildner O
    Curr Opin Mol Ther; 2003 Aug; 5(4):351-61. PubMed ID: 14513677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of viruses in the treatment of solid tumours.
    Bourke MG; Salwa S; Harrington KJ; Kucharczyk MJ; Forde PF; de Kruijf M; Soden D; Tangney M; Collins JK; O'Sullivan GC
    Cancer Treat Rev; 2011 Dec; 37(8):618-32. PubMed ID: 21232872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future prospects for oncolytic therapy.
    McCormick F
    Oncogene; 2005 Nov; 24(52):7817-9. PubMed ID: 16299540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
    Palmer DH; Chen MJ; Searle PF; Kerr DJ; Young LS
    Gene Ther; 2005 Aug; 12(15):1187-97. PubMed ID: 15800660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.